Talking Medicines builds a more defensible AI model for life sciences

Tern plc

Talking Medicines is moving beyond a simple large language model approach with an agentic AI architecture built specifically for life sciences.

The company’s strategy is based on a straightforward view: large language models are useful, but they are not enough on their own for regulated healthcare applications. They can process language, summarise information and generate responses, but they do not automatically provide the specialist scientific context, validated methodologies or governance required in life sciences.

Talking Medicines is addressing that limitation by combining large language models with proprietary healthcare intelligence, AI agents and an orchestration layer.

The proprietary intelligence sits at the centre of the architecture. It includes healthcare-specific classification models, behavioural intelligence derived from patient conversations, Emotional AI, evidence-based scoring frameworks, healthcare ontologies and specialist data science methods.

General-purpose AI models are becoming widely available. As access to those models broadens, competitive differentiation is likely to depend less on the underlying language model and more on proprietary data, specialist models, domain expertise and the ability to produce reliable outputs.

Talking Medicines is positioning its healthcare intelligence as that differentiating layer.

Its technology is designed to analyse unstructured healthcare conversations and convert them into structured, reproducible and explainable intelligence. That gives the company a clearer role than simply providing access to generative AI.

AI agents form the next part of the architecture. These agents are designed to carry out specific analytical tasks, select appropriate models, identify where more evidence is required and determine which patient groups or areas of analysis need further attention. Instead of relying on users to run separate queries or analyses, agents can coordinate parts of the workflow and connect insights with other systems and processes.

Talking Medicines is also adding an orchestration layer above those agents. This layer is designed to coordinate different models, data sources, agents and business systems.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Tern invests £78,000 in Device Authority through 8% convertible loan notes

Tern Plc has committed approximately £78,000 to new convertible loan notes issued by Device Authority, which carry 8% annual...

Device Authority highlights security risks as AI begins controlling physical machines

Device Authority examines the security risks of AI-controlled machinery and the role of device identity, authentication and access controls...

Talking Medicines targets better pharmaceutical launch results through message analysis

Talking Medicines' Message Resonance Score measures doctors' understanding of pharmaceutical messaging to help companies improve launch strategies....

Search